Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M923 PK and Safety Study: Auto-injector vs Prefilled Syringe
NCT02675023Phase 1Completed
- Sponsor
- Momenta Pharmaceuticals
- Start
- Jan 2016
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of BAX 2923 in rheumatoid arthritis (RA) and plaque psoriasis (2 arms), sponsored by Momenta Pharmaceuticals. Primary endpoints: Area under the concentration-time curve from 0 to infinity at Day 71, Area under the concentration-time curve from 0 to 336 hours and 1 more. Started Jan 2016; status: completed.
02
Drugs
BAX 2923
03
Conditions
rheumatoid arthritis (RA)plaque psoriasis
Beyond the preview
Go deeper on NCT02675023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02675023.